The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Nasser Ebrahimi Daryani; Babak Haghpanah; Ali Reza Sayyah; Ali Asad Hashtroudi; Mohammad Bashashati; Parisa Poursamimi; Mehri Nikbin

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Nasser Ebrahimi Daryani ^{1
, *} , Babak Haghpanah ² , Ali Reza Sayyah ² , Ali Asad Hashtroudi ² , Mohammad Bashashati ² , Parisa Poursamimi ² and Mehri Nikbin ²

Authors Information

¹ Tehran University of Medical Sciences, Imam Khomeini Hospital & Study Group of Interferon in Iran (SG.IFN.IR), nebrahim@sina.tums.ac.ir, Tehran, IR.Iran

² Tehran University of Medical Sciences, Imam Khomeini Hospital, Tehran, IR.Iran

Article information

Hepatitis Monthly: 4 (7); 71-74
Article Type: Research Article

To Cite: Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial, Hepat Mon. Online ahead of Print ; 4(7):71-74.

Abstract

Background and aims: Peginterferon alpha-2a is a known standard therapy for patients with chronic HCV infection. However efficacy and safety of this treatment is still unclear in regional settings. This study was designed to clarify efficacy and safety of peg-interferon based therapy in Iranian patients.
Methods: 23 patients were treated with Peginterferon alpha-2a in combination with ribavirin for 48 weeks. The patients were observed for adverse effects and response to therapy during treatment and 24 weeks after the end of therapy.
Results: Early virologic response, end of treatment response, and sustained virologic response rates were 86.9 % (20/23), 82.6 % (19/23), and 78.3 % (18/23) respectively. The most common adverse effects in descending order were flue-like symptoms (74%), mood changes (48%), and weight loss (43%).
Conclusion: Combination therapy with Peginterferon alpha-2a and ribavirin for 48 weeks is an effective treatment with minimal adverse effects.

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Hepatitis Monthly

Published by: Kowsar

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Article information

Abstract

Full Text

Readers' Comments

Hepatitis Monthly

Published by: Kowsar

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Article information

Abstract

Full Text

Share on:

Readers' Comments:

Readers' Comments